Singapore markets closed

Precision BioSciences, Inc. (DTIL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3300-0.0400 (-2.92%)
At close: 04:00PM EST
1.3800 +0.05 (+3.76%)
After hours: 06:44PM EST
Full screen
Loading interactive chart…
  • Business Wire

    Precision BioSciences Announces Change to its Board of Directors

    DURHAM, N.C., November 10, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. Raymond Schinazi is stepping down from the company’s Board of Directors and will continue as a member of the company’s SAB, lending his deep expertise in antiviral drug discovery and development.

  • Zacks

    Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates

    Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update

    DURHAM, N.C., November 08, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.